A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors

JAB-2485 is a small molecule Aurora A inhibitor. Inhibition of Aurora A activity at the cellular level induces apoptosis and inhibits tumor growth.

In this study, the sponsor and investigators want to learn:

• How much of the study drug can be given with an acceptable level of side effects
• The effects of the study drug (good and bad)
• How much of the study drug is absorbed into the blood and how fast it is removed
• How the study drug is acting on your body

If you decide to participate in this study, you will be asked to visit the study site approximately 4 times over the first 3weeks (Cycle 1), about 4 times during Cycle 2 if you are enrolled in dose escalation phase and about one time if you are enrolled in dose expansion phase, and about once since Cycle 3 and the subsequent cycles unless there is additional testing requested by study.